

Annual General  
Meeting  
19 November 2009



Robert Klupacs, CEO & Managing Director  
Circadian Technologies (ASX.CIR)

# Disclaimer

Investment in Circadian Technologies Limited ('Circadian') is subject to investment risk, including possible loss of income and capital invested. Neither Circadian nor any other member company of the Circadian Group guarantees any particular rate of return or performance, nor do they guarantee the repayment of capital.

This presentation is not an offer or invitation for subscription or purchase of or a recommendation of securities. It does not take into account the investment objectives, financial situation and particular needs of the investor. Before making any investment in Circadian, the investor or prospective investor should consider whether such an investment is appropriate to their particular investment needs, objectives and financial circumstances and consult an investment advisor if necessary.

This presentation may also contain forward-looking statements regarding the potential of the Company's projects and interests and the development and therapeutic potential of the Company's research and development. Any statement describing a goal, expectation, intention or belief of the Company is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercialising drugs that are safe and effective for use as human therapeutics and the financing of such activities. There is no guarantee that the Company's research and development projects and interests (where applicable) will receive regulatory approvals or prove to be commercially successful in the future. Actual results of further research could differ from those projected or detailed in this presentation. As a result, you are cautioned not to rely on forward-looking statements. Consideration should be given to these and other risks concerning research and development programs referred to in this presentation.

# Circadian Technologies Limited- 2009 AGM Presentation Outline

- **Review of achievements since June 2008**
- **Circadian - a developer of biologics based cancer therapies**
- **Cancer therapies/diagnostic pipeline - product development overview**
- **VEGF-C/D gene therapy - Ark Therapeutics Ltd and Lymphatix Ltd**
- **Expected milestones/value adding events next 6-18 months**
- **Circadian - the investment opportunity**



# Circadian's new direction since June 2008

Transformation of the business model from  
“biotechnology investor and incubator of early stage  
technologies” to  
focused developer of biological cancer therapies



# REVIEW OF ACHIEVEMENTS SINCE JUNE 2008

# Execution of new business strategy – objectives we set for 2008/2009

- Extend and strengthen core intellectual property covering VEGF-based therapeutics
- Advance drug development pipeline toward human clinical trials
- Add to list of partnerships for the commercialisation of our intellectual property
- Further strengthen and add skill-sets to management team

# Progress achieved in executing new business strategy - to date


- **Extending and strengthening IP position**
  - Acquisition of 100% of Vegenics
  - Prosecution of key strategic patents in USA, Europe and Japan
- **Advancing our product pipeline**
  - VGX-100: manufacturing of antibody (AB) drug underway
  - VGX-200: humanisation of AB's completed
  - VGX-300: manufacturing milestone achieved
  - Animal studies in cancer models underway for above programs
  - Licensee ImClone designated human AB IMC-3C5 as pre-clinical development candidate

# Progress achieved in executing new business strategy - to date (cont)

- **New partnerships**
  - Healthscope - developing and to commercialise cancer diagnostic
  - Perkin-Elmer granted license - research products market
- **Building the management and advisory team**
  - Establishment of Product Development Review Committee  
Six members with vast experience in international drug development
  - Expanded management team  
Alex Szabo, Head of Business Development  
Mike Gerometta, Head of Chemistry Manufacturing Control  
Mark Sullivan, Head of Clinical Development, recently appointed (ex GSK, Gilead Sciences)
  - Appointment of new director with drug development background, August 09: Dr Errol Malta (ex Amgen)
- **Divestment of non-core assets: Avexa**

## Key financials (consolidated)

	30 June 09	18 Nov 09 (unaudited)
	\$000	\$000
Cash	38,836	35,500
Listed investments (market value)	5,142	9,000
Net assets	38,773	
Revenue	3,091	
Operating expenses (incl. R&D, investment related exp's)	(12,966)	
Loss before tax	(9,875)	
Net cash outflows	(7,329)	
	NTA per share	
	\$0.86	
	Cash & listed assets per share	\$0.98
	\$0.97	
	Share price	\$0.73
	\$0.73	



# CIRCADIAN - A DEVELOPER OF BIOLOGICS BASED CANCER THERAPIES



# Focused developer of biologics based cancer therapies

- Developing **antibody therapies** to treat cancer
  - a major global opportunity
- Break through technology based on
  - **tumour starvation AND inhibition of spread**
- Partnered programs with **existing and increasing royalty streams**
  - leading international biotechs
- **Deep pipeline** of product opportunity
- Other disease applications
- **Dominant IP position**

# Strategy for extracting pipeline value

- Objective is to secure pre-clinical partnerships for one or more of our therapeutic programs
- Retain development of one selected therapeutic to proof of efficacy in humans - partner thereafter
- Selectively exploit / commercialise other aspects of portfolio:
  - therapeutics outside oncology area
  - clinical diagnostics and reagents for early revenues

# Antibodies: A rich deal environment

- Antibodies are one of the most valuable sectors of the market
  - 21 antibody drugs on the market
  - Mostly in cancer and inflammation
  - Current sales of top ten antibodies > \$US20B pa
  - Total sales growing by >30% annually
  - Greater competitive barrier to entry
  - Targeted profiles = cost vs health economic advantage

By 2014 it is expected that 4 of the top 6 best-selling drugs will be antibodies & the top 10 selling drugs will come from biotech (source: EvaluatePharma®)

# Oncology Antibodies: High Value Pre-clinical Deals

Parties	Date	Size	Technology
BioInvent/Thrombogenics /Roche	Jun 08	\$US800M	Exclusive licence to PIGF Abs in oncology. \$US75M upfront. \$US700M milestones. Double digit royalties
Micromet/Bayer-Schering	Jan 09	\$US396M	Option to Ab against undisclosed oncology target
Abbott/LICR	Nov 08	\$US150-200M	Exclusive licence to 2 <sup>nd</sup> generation EGFR Ab in oncology which has completed 8 person Phase 1 study
Dyax/Sanofi-Aventis	Feb 08	\$US500M	Exclusive licence to Tie-1 Ab DX-2240 and phage display in selected applications
GSK/OncoMed	Dec 07	\$US1.4B	Exclusive licence/co-development of 4 selected stem cell Abs in cancer

# Circadian's Technology: Inhibiting tumour growth & spread by VEGF blockade

- Our technology is centred on two members of the VEGF family of proteins: VEGF-C & VEGF-D and their activation on VEGF receptors VEGFR-2 and VEGFR-3
- These proteins promote blood and lymphatic vessel development
- Targeting this process has major potential to limit tumour growth and spread
- Also has applications in other diseases such as eye diseases

# A major commercial opportunity

- Avastin®: Effective but not across the board
  - Not all patients respond to therapy (30-50% response rate)
  - 25-50% of responders become “resistant” within 12 to 18 months
  - Likely reasons:
    - Tumour growth due to factors other than VEGF-A; and/or
    - Other angiogenic factors being turned on when VEGF-A blocked (i.e. VEGF-C, VEGF-D)


Avastin  
effective but =  
has limitations

Major  
opportunity  
for CIR


Our technology  
builds upon the  
Avastin application



# Mechanism of Circadian's Drugs (1)




# Mechanism of Circadian's Drugs (2)





# CANCER THERAPIES/DIAGNOSTIC PIPELINE - PRODUCT DEVELOPMENT OVERVIEW

# Circadian's Deep Product Pipeline




# VGX-100 (human anti-VEGF-C antibody)

- 11 different animal studies ongoing; more planned-initial results H1 2010
- Manufacturing methods being developed to produce compounds for clinical use (cGMP)
- FDA pre-IND review H1 2010
- IND filing expected H1 2011

# IMC-3C5 (human anti VEGFR-3 antibody) being developed by ImClone

- Significant animal proof of principal established in cancer models
- Designated formal clinical development candidate
- IND filing expected H2 2010

# VEGFR-3 Ab +/- chemo in Non-Small Cell Lung Cancer xenograft model (NCI-H292)



NSCLC xenograft model  
(NCI-H292)



# Cancers of Unknown Primaries (CUP) Molecular Diagnostic Near term revenue generating asset

- Development partnered with Healthscope (ASX:HSP)
  - US incidence of CUP 60,000 to 100,000 per annum
  - Test to sell for between US\$2-4K due to significant health cost savings
  - CIR retains ownership and exclusive commercialisation rights in US, Europe and Japan; receive royalty on Healthscope sales
  - Healthscope (Aus, NZ, Singapore, Malaysia)
  - **Product launch expected H2 2010**

## Landmark trial for cancer tool

**Olga Galacho**  
**EXCLUSIVE**

CIRCADIAN Technologies last night signed on major private hospital operator Healthscope to test and market a breakthrough cancer diagnostic tool.

years, will help pathology laboratories identify the hidden source of secondary cancers.


Circadian chief executive Robert Klupacs said he expected the company to make other similar announcements in coming months, leveraged off last year's acquisition of Ludwig Institute Vegenics assets.

"I think this deal will surprise the

was confident the potential partnerships in Circadian's pipeline were impressive.

One of the most cash-rich life science companies in Australia with more than \$42 million in the bank, Circadian owes its financial position in part to a \$25 million investment by the late Kerry Packer about 10 years ago.






VEGF-C/D GENE THERAPY:  
Ark Therapeutics Ltd & Lymphatix Ltd

# Gene therapy licences - background


- Ark Therapeutics (2001)- non exclusive licence to VEGF-D gene used in combination with Ark delivery device for treatment of stenosis (“Trinam”)
- Lymphatix Ltd (2004) - exclusive licence for VEGF-C and VEGF-D gene therapy excluding cancer and excluding rights previously granted to Ark.
- Ark acquired Lymphatix in January 2008

# Ark's Phase 3 Product Trinam®


- VEGF-D gene therapy product
- Extends lifetime of dialysis access grafts by keeping veins open for longer. Phase 2 clinical trials: 17 months v 4.5 months.
- Major patient impact by reduced need for repeated surgery and increased survival time of patients undergoing ongoing dialysis.
- Market estimates > \$US750M+ per annum



Step 1: Surgical isolation of vein and artery



Step 2: Insert flexible plastic tube graft to provide access for dialysis



# Gene therapy - Circadian termination of Ark licence

- Post Lymphatix acquisition Ark asserts it no longer requires original 2001 licence and does not pay annual fee
- Circadian subsidiary terminates Ark licence for non-payment of licence fees in October 2009
- Circadian initiates arbitration under Lymphatix agreement to clarify scope
- Circadian confident of its position
- Expect resolution in 6-12 months





EXPECTED MILESTONES/VALUE ADDING EVENTS  
NEXT 6 to 18 months

# Upcoming milestones & events

- VGX-100 cancer drug development program
  - Animal tumour model evaluation H1 2010
  - FDA pre-IND review H1 2010
  - Toxicology completion H2 2010
  - IND Filing H1 2011
- IND filing: IMC-3C5 for cancer (ImClone/Eli Lilly partner) H2 2010
- CUP molecular diagnostic H2 2010
  - Market launch

# Upcoming milestones & events (cont)

- ANP (listed investment\*) milestone Q1 2010
  - Antisense Therapeutics' (ASX:ANP) partner Teva to advise of decision to progress MS treatment ATL/TV 1102 into late stage clinical studies
  
- Resolution of unlicensed gene therapy development by third parties H2 2010

\* CIR's direct+indirect interest in ANP: 21.8%

# An investment with significant upside

- Therapeutic antibodies
  - Major focus of big pharma
  - High value early stage deal opportunities and M&A opportunities
- Deep diverse product pipeline
  - Diagnostic product in late stage development
  - Potential multi-million dollar royalties
  - Royalty flows possible <12 months
- Angiogenesis - significant product opportunity validated
- Dominant and protected IP position
- World-class drug development expertise and management
- Strong financial position

## An investment with significant upside (cont)

US Investment bank Merriman Curhan Ford published analyst opinion 5 November 2009:

*" We believe the current valuation of Circadian represents an attractive entry point for investors based on the potential of its product candidates. "*